US Bancorp’s United Therapeutics UTHR Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$968K Buy
1,787
+209
+13% +$118K ﹤0.01% 1215
2026
Q1
$936K Buy
1,578
+52
+3% +$25.9K ﹤0.01% 1183
2025
Q4
$744K Sell
1,526
-647
-30% -$301K ﹤0.01% 1309
2025
Q3
$911K Sell
2,173
-126
-5% -$42.4K ﹤0.01% 1182
2025
Q2
$661K Buy
2,299
+328
+17% +$98K ﹤0.01% 1333
2025
Q1
$608K Buy
1,971
+215
+12% +$73.7K ﹤0.01% 1361
2024
Q4
$620K Sell
1,756
-23
-1% -$8.45K ﹤0.01% 1381
2024
Q3
$638K Sell
1,779
-3
-0.2% -$1.01K ﹤0.01% 1366
2024
Q2
$568K Buy
1,782
+125
+8% +$33.1K ﹤0.01% 1401
2024
Q1
$381K Sell
1,657
-647
-28% -$146K ﹤0.01% 1662
2023
Q4
$507K Buy
2,304
+446
+24% +$103K ﹤0.01% 1481
2023
Q3
$420K Sell
1,858
-182
-9% -$41.9K ﹤0.01% 1460
2023
Q2
$450K Buy
2,040
+135
+7% +$29.9K ﹤0.01% 1459
2023
Q1
$427K Buy
1,905
+461
+32% +$114K ﹤0.01% 1487
2022
Q4
$402K Sell
1,444
-629
-30% -$159K ﹤0.01% 1506
2022
Q3
$434K Buy
2,073
+134
+7% +$30K ﹤0.01% 1461
2022
Q2
$456K Sell
1,939
-181
-9% -$36.8K ﹤0.01% 1494
2022
Q1
$380K Sell
2,120
-4
-0.2% -$762 ﹤0.01% 1659
2021
Q4
$460K Sell
2,124
-217
-9% -$42.6K ﹤0.01% 1568
2021
Q3
$433K Buy
2,341
+317
+16% +$62.4K ﹤0.01% 1593
2021
Q2
$363K Sell
2,024
-115
-5% -$21.9K ﹤0.01% 1708
2021
Q1
$358K Sell
2,139
-281
-12% -$46.9K ﹤0.01% 1666
2020
Q4
$368K Sell
2,420
-2,788
-54% -$366K ﹤0.01% 1598
2020
Q3
$526K Sell
5,208
-1,580
-23% -$173K ﹤0.01% 1306
2020
Q2
$821K Buy
6,788
+1,488
+28% +$167K ﹤0.01% 1041
2020
Q1
$503K Buy
5,300
+2,579
+95% +$245K ﹤0.01% 1192
2019
Q4
$240K Buy
2,721
+742
+37% +$65.3K ﹤0.01% 1735
2019
Q3
$158K Buy
1,979
+499
+34% +$40.2K ﹤0.01% 1925
2019
Q2
$116K Sell
1,480
-280
-16% -$26.2K ﹤0.01% 2128
2019
Q1
$207K Sell
1,760
-4,531
-72% -$528K ﹤0.01% 1798
2018
Q4
$685K Sell
6,291
-217
-3% -$25.2K ﹤0.01% 1185
2018
Q3
$833K Buy
6,508
+117
+2% +$14.5K ﹤0.01% 1205
2018
Q2
$723K Buy
6,391
+863
+16% +$94.9K ﹤0.01% 1274
2018
Q1
$621K Buy
5,528
+203
+4% +$25.8K ﹤0.01% 1344
2017
Q4
$788K Buy
5,325
+1,195
+29% +$152K ﹤0.01% 1223
2017
Q3
$484K Sell
4,130
-45
-1% -$5.75K ﹤0.01% 1428
2017
Q2
$541K Buy
4,175
+128
+3% +$16K ﹤0.01% 1373
2017
Q1
$548K Buy
4,047
+225
+6% +$34.1K ﹤0.01% 1363
2016
Q4
$548K Buy
3,822
+1,802
+89% +$230K ﹤0.01% 1321
2016
Q3
$239K Sell
2,020
-393
-16% -$47.2K ﹤0.01% 1678
2016
Q2
$256K Sell
2,413
-626
-21% -$69.8K ﹤0.01% 1610
2016
Q1
$340K Buy
3,039
+21
+0.7% +$2.66K ﹤0.01% 1456
2015
Q4
$472K Sell
3,018
-158
-5% -$23K ﹤0.01% 1321
2015
Q3
$417K Buy
3,176
+352
+12% +$56.5K ﹤0.01% 1376
2015
Q2
$492K Sell
2,824
-1,695
-38% -$305K ﹤0.01% 1360
2015
Q1
$780K Sell
4,519
-487
-10% -$74.2K ﹤0.01% 1141
2014
Q4
$649K Sell
5,006
-1,283
-20% -$165K ﹤0.01% 1207
2014
Q3
$809K Sell
6,289
-4,979
-44% -$513K ﹤0.01% 1067
2014
Q2
$997K Sell
11,268
-11,250
-50% -$1.08M ﹤0.01% 1003
2014
Q1
$2.12M Sell
22,518
-1,076
-5% -$110K 0.01% 675
2013
Q4
$2.67M Sell
23,594
-3,367
-12% -$304K 0.01% 564
2013
Q3
$2.13M Buy
26,961
+1,773
+7% +$130K 0.01% 610
2013
Q2
$1.66M Buy
+25,188
New +$1.62M 0.01% 672

Other funds holding UTHR

US Bancorp's UTHR Position: Q2 2026 in Review

US Bancorp increased its United Therapeutics (UTHR) stake by 13% in Q2 2026, buying an estimated $118K and bringing the position to 1,787 shares worth $968K. The position accounts for ﹤0.01% of the portfolio, ranked #1215.

US Bancorp first reported a position in UTHR in Q2 2013 and has held it in 53 quarters since. The position peaked at $2.67M in Q4 2013. 875 funds tracked by Wall St. Rank hold UTHR as of Q2 2026.

  • US Bancorp held 1,787 shares of United Therapeutics worth $968K as of Q2 2026.
  • US Bancorp bought 209 United Therapeutics shares in Q2 2026, an estimated $118K.
  • United Therapeutics made up ﹤0.01% of US Bancorp's portfolio in Q2 2026, its #1215 holding.
  • US Bancorp first reported a position in United Therapeutics in Q2 2013 and has held it in 53 quarters since.
  • US Bancorp's United Therapeutics position peaked at $2.67M in Q4 2013.
  • 875 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2026.

Based on US Bancorp's 13F filing for Q2 2026, filed 12 Aug 2026.